Member Info for Mavern

Clear evidence that the serious investors won’t be waiting until October, they like to get in early

I disagree. The markets are very forward-looking and this will start moving north many months ahead of the October FDA deadline

Agree Osaka, we continue to fly very much under the radar, one of the best potential stocks on AIM

We should feel privileged that Allah4 see’s GDR as the biggest threat to his existing investments (ODX and AVCT) and is prepared to spend so much of his time on here de-ramping. Even before our commercialisation agreement he was running scared. Easy solution would be to switch his investments over but guess he’s become emotionally attached to his longstanding investments which is a common trait of novice investors.

That’s not the first time I’ve heard that AMB, makes you wonder if the feed comes from a central place e.g. LSE? Hopefully V O X can sort it :-)

V O X still not sending out RNS alerts for ECR. Very frustrating as I was not aware of Friday’s RNS until after market hours, and would’ve added to my position had I known. Likely that others would too, including new investors. It’s not just about the early indicator positivity of this announcement, it’s also about the elimination of any negative find announcement. I’ve emailed V O X customer support drawing their attention to the issue

“Whilst we are above 140 the upside should continue” https://www.share-talk.com/share-talk-bulletin-board-heroes-wednesday-10th-february-2021/

Can’t believe how much under the radar this still is. Huge potential before covid, but long covid is an absolute game changer. Unique transformational technology, no competition, significantly undervalued, what’s not to like!

AVCT with commercial agreement up 6.5%. GDR with no news up 14%. GDR still has ludicrously low market cap versus the competition with arguably much better prospects. Let the re-rate continue! :-)

I think GDR was, and still is, very oversold and the uniqueness of their product, especially the shortly to be launched PCR test, has been very under appreciated by the market. I also think the sales deal(s) will be very sizeable and could take the market by surprise. You only have to join the dots together to conclude this. Mostly though I see incredible value here just by looking at the GDR market cap (£62M) versus AVCT (£322M) and NCYT (£570M)

I think Magsy may have

I think even Magsy would struggle to put a negative spin on today’s news! :-))

PJ - according to the POLX website the hyperpolarised gas MRI is used to evaluate the effectiveness of bronchial stents in improving ventilation for COPD patients

Nice 10% rise last week as the inevitable re-rate gathers pace. So much potential to be un-locked here and will be invaluable for treatment of numerous cases of long covid and many other conditions - general pulmonary disease, cystic fibrosis, Asthma and stent placement, all in a clean non-intrusive radiation free environment. No real competition either so captive global market.

Sorry €0.032 !!

€0.32 currently in Frankfurt and Berlin listing

I don’t think the market has fully appreciated the significance of yesterday‘s news. This de-risks the entire project enormously and introduces clarity , credibility and enhanced opportunity to the path ahead

We are almost the same distance away from FDA approval now as we were early October when we applied for four months accelerated FDA approval. Approval is more or less a given as it’s a medical device, not a drug. Despite Fridays rise the share price is still significantly undervalued, fair value should be above 100 right now

It’s called share price “normalisation”. This is way oversold.

If you’re looking for lower entry Dibs I highly doubt you’re going to get much better than where the share price is today. FDA primarily is for the US but there is a global market out there and Polarean has a captive market without competition. In any case, October FDA is getting remarkably close now in investment terms.